As long as the best vascular surgeons in the area are held up, there will be trouble with the rest. It is a new field, and clinical trials are what these scientists want to do. That's why I told them, they don't need an IRB so much as they need a private eye, to attend the board meetings.
There *are* reports of unexpected failures to diagnose and to treat, and we need the best, to step up and demand to be allowed to study this. Or we risk not meeting the needs of hundreds of thousands of Americans, and potential foreign customers, for the sake of some doomed drug therapies. Throwing out the baby, the bathwater, and the tub.
Time wounds all heels (Marx) but there is always tendon surgery (Achilles).